These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 39381015)

  • 1. High-Risk HLA-DQ Mismatches Are Associated With Adverse Outcomes After Lung Transplantation.
    Kleid L; Walter J; Moehnle P; Wichmann C; Kovács J; Humpe A; Schneider C; Michel S; Kneidinger N; Irlbeck M; Fertmann J; Dick A; Kauke T
    Transpl Int; 2024; 37():13010. PubMed ID: 39381015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of HLA Eplet Mismatch on De Novo Donor Specific Antibody Formation After Kidney Transplantation.
    Yanyiam P; Kantachuvesiri S; Thammanichanond D
    Transplant Proc; 2024 Apr; 56(3):515-520. PubMed ID: 38368130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-DQ mismatches stimulate de novo donor specific antibodies in heart transplant recipients.
    Zhang X; Kransdorf E; Levine R; Patel JK; Kobashigawa JA
    Hum Immunol; 2020 Jul; 81(7):330-336. PubMed ID: 32307126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. De Novo DQ Donor-Specific Antibodies Are Associated with Chronic Lung Allograft Dysfunction after Lung Transplantation.
    Tikkanen JM; Singer LG; Kim SJ; Li Y; Binnie M; Chaparro C; Chow CW; Martinu T; Azad S; Keshavjee S; Tinckam K
    Am J Respir Crit Care Med; 2016 Sep; 194(5):596-606. PubMed ID: 26967790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of molecular matching tools for the development of donor specific HLA-antibodies in patients undergoing lung transplantation.
    Kleid L; Walter J; Vorstandlechner M; Schneider CP; Michel S; Kneidinger N; Irlbeck M; Wichmann C; Möhnle P; Humpe A; Kauke T; Dick A
    HLA; 2023 Sep; 102(3):331-342. PubMed ID: 37068792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes.
    Wiebe C; Pochinco D; Blydt-Hansen TD; Ho J; Birk PE; Karpinski M; Goldberg A; Storsley LJ; Gibson IW; Rush DN; Nickerson PW
    Am J Transplant; 2013 Dec; 13(12):3114-22. PubMed ID: 24164958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eplet Mismatch Load and
    Senev A; Coemans M; Lerut E; Van Sandt V; Kerkhofs J; Daniëls L; Driessche MV; Compernolle V; Sprangers B; Van Loon E; Callemeyn J; Claas F; Tambur AR; Verbeke G; Kuypers D; Emonds MP; Naesens M
    J Am Soc Nephrol; 2020 Sep; 31(9):2193-2204. PubMed ID: 32764139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human leukocyte antigen epitope mismatch loads and the development of de novo donor-specific antibodies in cardiothoracic organ transplantation.
    Bedford A; Jervis S; Worthington J; Lowe M; Poulton K
    Int J Immunogenet; 2022 Feb; 49(1):30-38. PubMed ID: 34904369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. De novo DQ donor-specific antibodies are associated with worse outcomes compared to non-DQ de novo donor-specific antibodies following heart transplantation.
    Cole RT; Gandhi J; Bray RA; Gebel HM; Morris A; McCue A; Yin M; Laskar SR; Book W; Jokhadar M; Smith A; Nguyen D; Vega JD; Gupta D
    Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28181305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early clearance vs persistence of de novo donor-specific antibodies following lung transplantation.
    Islam AK; Sinha N; DeVos JM; Kaleekal TS; Jyothula SS; Teeter LD; Nguyen DTM; Eagar TN; Moore LW; Puppala M; Wong STC; Knight RJ; Frost AE; Graviss EA; Osama Gaber A
    Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28658512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donor selection in pediatric kidney transplantation using DR and DQ eplet mismatching: A new histocompatibility paradigm.
    Bryan CF; Chadha V; Warady BA
    Pediatr Transplant; 2016 Nov; 20(7):926-930. PubMed ID: 27448994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of risk epitope mismatches associated with de novo donor-specific HLA antibody development in cardiothoracic transplantation.
    McCaughan JA; Battle RK; Singh SKS; Tikkanen JM; Moayedi Y; Ross HJ; Singer LG; Keshavjee S; Tinckam KJ
    Am J Transplant; 2018 Dec; 18(12):2924-2933. PubMed ID: 29847022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eplet mismatch scores and de novo donor-specific antibody development in simultaneous pancreas-kidney transplantation.
    Ladowski JM; Mullins H; Romine M; Kloda D; Young C; Hauptfeld-Dolejsek V; Houp J; Locke J
    Hum Immunol; 2021 Mar; 82(3):139-146. PubMed ID: 33390268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of human leukocyte antigen immunologic risk stratification methods in lung transplantation.
    Hiho SJ; Levvey BJ; Diviney MB; Snell GI; Sullivan LC; Westall GP
    Am J Transplant; 2024 May; 24(5):827-838. PubMed ID: 37981213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association between human leukocyte antigen eplet mismatches, de novo donor-specific antibodies, and the risk of acute rejection in pediatric kidney transplant recipients.
    Sharma A; Taverniti A; Graf N; Teixeira-Pinto A; Lewis JR; Lim WH; Alexander SI; Durkan A; Craig JC; Wong G
    Pediatr Nephrol; 2020 Jun; 35(6):1061-1068. PubMed ID: 32065279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA Matching at the Eplet Level Protects Against Chronic Lung Allograft Dysfunction.
    Walton DC; Hiho SJ; Cantwell LS; Diviney MB; Wright ST; Snell GI; Paraskeva MA; Westall GP
    Am J Transplant; 2016 Sep; 16(9):2695-703. PubMed ID: 27002311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor-Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes Independently Predicts the Incidence of De Novo Donor-Specific HLA Antibodies Following Renal Transplantation.
    Lachmann N; Niemann M; Reinke P; Budde K; Schmidt D; Halleck F; Pruß A; Schönemann C; Spierings E; Staeck O
    Am J Transplant; 2017 Dec; 17(12):3076-3086. PubMed ID: 28613392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eplet mismatches associated with de novo donor-specific HLA antibody in pediatric kidney transplant recipients.
    Charnaya O; Jones J; Philogene MC; Chiang PY; Segev DL; Massie AB; Garonzik-Wang J
    Pediatr Nephrol; 2021 Dec; 36(12):3971-3979. PubMed ID: 34100108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development.
    Wiebe C; Rush DN; Nevins TE; Birk PE; Blydt-Hansen T; Gibson IW; Goldberg A; Ho J; Karpinski M; Pochinco D; Sharma A; Storsley L; Matas AJ; Nickerson PW
    J Am Soc Nephrol; 2017 Nov; 28(11):3353-3362. PubMed ID: 28729289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Racial differences in incident de novo donor-specific anti-HLA antibody among primary renal allograft recipients: results from a single center cohort study.
    Everly MJ; Briley KP; Haisch CE; Dieplinger G; Bolin P; Kendrick SA; Morgan C; Maldonado AQ; Rebellato LM
    Transpl Int; 2017 Jun; 30(6):566-578. PubMed ID: 28211192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.